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Background: Rates of invasive vancomycin-resistant Enterococcus (VRE) in the USA remains on the rise. Efforts to
control vancomycin use and nosocomial transmission have had limited success in halting the spread of this pathogen.
The role of antibiotic exposure remains a topic of controversy. We evaluated the association between emergence of
VRE-blood-stream infections (BSI), aggregate and individual-patient vancomycin- exposure, and clonal transmission of
VRE at an academic pediatric tertiary care hospital.
Methods: E. faecium and E. faecalis isolates recovered from blood specimens from hospitalized children from
2003–2010 were retrieved from the microbiology database. Aggregate vancomycin use and individual-patient
vancomycin exposure 6 months preceding each event of bacteremia were recorded. Pulse-field electrophoresis
was performed on selected VRE isolates.
Results: Of 151 episodes of E. faecium and E. faecalis BSI among hospitalized children <18 years of age, 9% (14)
were due to VRE. Of these, 5 (36%) were due to nosocomial transmission. Aggregate (r .19, P = 0.3) and
individual-patient vancomycin-exposure (X2 = .26; P = .87) were not associated with VRE-BSI. On bivariate analysis,
OR for developing VRE-BSI among patients infected with clonal isolates was 36 (P < .0001). Infection control
interventions, rather than antimicrobial stewardship interventions to decrease vancomycin use, proved to be
effective in reducing the rates of VRE-BSI.
Conclusions: In our experience, VRE-BSI was associated with nosocomial transmission and was independent of
aggregate and individual-patient vancomycin-exposure. Molecular epidemiology is a crucial tool to differentiate
the role of nosocomial transmission and antibiotic exposure in the emergence of invasive VRE infections among
hospitalized children.
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Over the past two decades, the emergence of vancomycin-
resistant Enterococcus (VRE) as a nosocomial pathogen
has been attributed to a complex interaction of epidemio-
logic forces including nosocomial transmission and anti-
microbial pressure [1-3]. In particular, the use of selected
antibiotics such as vancomycin, expanded-spectrum ceph-
alosporins, and agents with potent anaerobic activity has
been found to promote individual patients to gastrointes-
tinal colonization with VRE [4]. Nevertheless, the role of* Correspondence: cecilia.dipentima@vanderbilt.edu
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article, unless otherwise stated.antibiotic exposure in both colonization and infection re-
mains controversial [3,5,6]. Efforts to control vancomycin
use and nosocomial transmission have had limited suc-
cess, and rates of invasive VRE in the USA remains on the
rise [7]. Furthermore, mortality and hospital costs associ-
ated with VRE-BSI are significantly high, especially among
immunocompromised patients [8].
We sought to evaluate the association between aggregate
and individual-patient vancomycin-exposure, clonal trans-
mission among hospitalized children and rates of VRE-BSI
at a tertiary-care children hospital. To the best of our know-
ledge this is the first study addressing individual-patient
and aggregate vancomycin exposure and nosocomial trans-
mission using pulse-field electrophoresis to determine risk
factors associated with VRE-BSI in pediatric patients.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patients and settings
The study was performed at Alfred I. duPont Hospital for
Children, Wilmington, DE, a tertiary, 180-bed, academic
hospital affiliated with Thomas Jefferson University
(Philadelphia, PA) [9,10]. From April 1st, 2003 to March
31st, 2010 clinical blood cultures reporting E. faecalis
and E. faecium among hospitalized children were retrieved
from the Microbiology Laboratory database. Records of
the annual rates of solid organ transplants (SOT) (kidney,
liver and heart transplants) and hematopoietic stem-cell
transplant (HSCT) were obtained from the hospital execu-
tive statistical summary and the HSCT program.
Laboratory methods
One isolate per patient per year was included in the
analysis. E. faecium and E. faecalis isolates were identi-
fied following standard procedures at Alfred I. duPont
Hospital microbiology laboratory. From April 1, 2003
to June 30, 2008, vancomycin susceptibility testing was
performed by Etest® (AB Biodisk, BioMerieux, S.A.,
Marcy I’Etoile, France), and from July 1, 2008 to March
31, 2010, using a semi-automated system (MicroScan;
Dade Behring, West Sacramento, CA).
Pulsed-field electrophoresis (PFGE) for selected isolates
was performed at a reference laboratory (ARUP Laboratories,
Salt Lake City, UT) [11]. Isolates were classified based
on published criteria as indistinguishable, closely-related,
and unrelated [12].
Infection control practices
Active surveillance for hospital-associated BSI was rou-
tinely performed by the infection control department. In
October 2007, an increased number of VRE-BSI was
noted among transplant patients hospitalized in the
Pediatric Intensive Care Unit. Surveillance stool cultures
was implemented for patients admitted to the intensive
case care, HSCT and oncology units upon admission
and weekly until discharge in October 2008.
Measures of antibiotic use
Aggregate vancomycin use April 1st, 2003 to March
31st, 2010 were captured by number of doses adminis-
tered (DA) to each unique patient and normalized per
1000 patient-days to control for differences in the annual
hospital census [9]. Vancomycin therapy, expressed as
the number of DA and days of therapy (DoT), for each
individual patient during the 6 months preceding each
event of E. faecalis and E. faecium BSI was recorded.
Analysis
Temporal trends of aggregate vancomycin use per 1000
patient-days were analyzed using a X2 test trend for pro-
portions. Spearman’s correlation coefficient was used toevaluate the association between aggregate vancomycin
use and VRE BSI; and rates of SOT and HSCT and rates
of VRE BSI. Chi-square was used to evaluate the distri-
bution of individual-patient vancomycin-exposure and
VRE-BSI. Logistic regression analysis was used to exam-
ine the association of VRE-BSI and clonal transmission,
while controlling for age and gender. All tests were two-
tailed with a .05 as the level of significance. Analyses
were performed using IBM-SPSS Software (Version 20.0,
IBM Corp) and Statistical software R (Version 2.10.2).
The Institutional Review Board of Nemours approved
this study.
Results
E. faecium and E. faecalis blood-stream infections
From April 1st, 2003 to March 31st, 2010, we identified
151 episodes of E. faecium and E. faecalis bacteremia in
101 pediatric patients (46 females; 55 males). Demo-
graphic characteristics are depicted in Table 1. The ma-
jority (137 of 151; 88%) of Enterococci BSI were due to
vancomycin-susceptible E. faecium and E. faecalis (VSE).
Of these, E. faecalis and E. faecium were responsible for
104 (76%) and 33 (24%) episodes of BSI, respectively. In-
fants less than one year of age represented 42% (57 of
137) of all episodes of VSE-BSI.
Fourteen (14 of 151, 9.2%) episodes of bacteremia
were associated with VRE in 11 individual patients
(Table 1). One small-bowel transplant patient had three
episodes of VRE blood-stream infections over a 4-year
period. The first and third episode (2004 and 2007),
were caused by E. faecium, while the second episode was
caused by E. faecalis (2005). A renal transplant patient
had two episodes of bacteremia 10 months apart. In the
unadjusted model, girls were more likely to develop
VRE-BSI (OR = 1.45; P = .63) (Table 1). When compared
with younger and older children, those between 2 and
6 years of age were at higher risk of developing VRE
blood-stream infection (OR = 3.8; CI = 1-14; P = .055).
VRE-BSI were sporadic between April, 2003 and July,
2008 (Figure 1). Rates of VRE-BSI peaked during the last
two quarters of 2007, and declined after strict infection
control measures and surveillance were implemented
(Figure 1). Of the 5 patients with VRE-BSI between
September, 2007 and April, 2008, 4 were associated with
vancomycin-resistant E. faecium. Three had undergone
HSCT (two infants received cord-blood transplantation
for congenital hemophagocytic syndrome, and the third
patient underwent autologous peripheral blood stem
cell for metastatic retinoblastoma) and one patient had
undergone liver and renal transplantation. One additional
liver transplant patient developed vancomycin-resistant
E. faecalis bacteremia. The overall mortality among trans-
plant patients was 50%; however, the case fatality rate
among HSCT patients was 67%, despite prompt and
Table 1 Demographic characteristics of Enterococcus faecium and Enterococcus faecalis blood-stream infections at
Alfred I. duPont Hospital for Children, 2003-2010
Characteristics Total N = 151 N = 14 (%) Vancomycin-Susceptible Enterococcus spp N = 137 (%)
E. faecalis E. faecium E. faecalis E. faecium
N = 3 (21) N = 11 (79) N = 104 (76) N = 33 (24)
Median age in years (range) 1 (0-20) 3 (0 - 4) 4 (0 - 16) 1 (0-20) 1 (0 - 19)
Male, No (%) 82 (54) 1 (1) 4 (5) 58 (71) 19 (23)
CR-BSI*, No (%) 101 (68) 3 (3) 6 (6) 66 (65) 26 (26)
*Catheter-related blood-stream infection.
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SOT patients. We did not find a statistically significant
correlation between rates of HSCT (r = .44, P = .3) and
SOT (r = .22, P = .6), and rates of VRE-BSI.
Between September, 2007 and April, 2008, 17 isolates
(5 from blood and 12 from stool) were submitted
for PFGE to determine clonality. Of these, 5 isolates
were indistinguishable (29%; 5/17). Four of these were
among the E. faecium isolates recovered from patients
with blood-stream infections. Three additional E. faecium
isolates were closely-related and 5 other strains were
unrelated. On bivariate analysis, the odds ratio for de-
veloping VRE blood-stream infection for patient with
clonal transmission was 36 (CI = 7-167; P < .0001). After
controlling for age and gender, this odds ratio was 41.5
(CI = 7-250; P < 0.001).
A single patient developed VRE-BSI between April,
2008 and March, 2010.
Infection control interventions
Contact precautions were implemented in all newly admit-
ted patients pending the results of the stool surveillance
cultures. Patients with negative results were removed from
contact isolation, but weekly screening continued duringFigure 1 Rates of vancomycin-resistant of E. faecalis and E. faecium b
as the number of doses administered per 1000 patient-days), Alfred Ithe length of their hospitalization. Infection control
policies included: 1. Staff were required to wear gowns
and gloves, and perform hand hygiene before and
after entering a room. 2. Patients remained in their
room without access to common places. 3. Patients trav-
eling to another part of the hospital used gown and
gloves. 4. ‘Terminal cleaning’ was performed after pa-
tient’s discharge. Additional interventions included: 1.
“Bare Below the Elbows” rule, eliminating white coats,
jackets, ties and jewelry. 2. Dedicated equipment and
supplies to isolation rooms. 3. Reinforcement of house-
cleaning activities: spot-cleaning high touch surfaces
with CaviWipes and de-cluttering of the rooms. 4.
Limit toys available in the rooms. Skin de-colonization
of colonized patients was implemented using Sage 2%
CHG cloths.
Vancomycin exposure
Following the implementation of an antimicrobial steward-
ship program in 2004, the use of vancomycin decreased
from 378 DA/1000 patient-days per year in 2003–2004
to 173 DA/1000 patient-days per year in 2009–2010
(P = <0.001) [10,13]. Vancomycin use was not associated
with increased use of other anti-staphylococcal antibioticslood-stream infections and aggregate vancomycin use (expressed
. duPont Hospital for Children, April 1, 2003- March 31st, 2010.
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did not correlate with rates of VRE-BSI (r = .19, P = 0.3).
Of the 151 episodes of E. faecalis and E. faecium BSI,
105 (69.5%) were documented in patients who received at
least one dose of vancomycin within the previous 6 months.
Individual-patient vancomycin-exposure was not associ-
ated with an increased risk for VRE-BSI (X2 = .26, P = .87).
On average, previous vancomycin-exposure among pa-
tients with VSE-BSI was 32 DA (range, 1–196) and 14 DoT
(range, 1–68). Patients who developed VRE-BSI received
24 DA (range, 2–68) and 13 DoT (range, 1–196) of vanco-
mycin prior to their events of bacteremia.
Discussion
Enterococcus spp. bacteremia is common in children with
intraluminal pathology and at higher risk for gastrointes-
tinal translocation. In our experience, the majority of
Enterococcus spp BSI were noted in infants and the major-
ity of these were associated with VSE. Conversely, VRE-
BSI was mainly seen in immunocompromised children,
the majority, undergoing transplantation. Since the first
hospital-acquired VRE infection was described in France,
rates of VRE infections remain on the rise [2,7]. Selective
antibiotic pressure and environmental contamination are
well described risk factors associated with acquisition
of VRE [14]. Antibiotics without activity against VRE
achieving high concentrations in the gastrointestinal tract
have been shown in humans and animal models to pro-
mote VRE colonization [6]. In our experience, nosocomial
transmission was associated with emergence of VRE-BSI
among the most vulnerable patient populations. Nosoco-
mial transmission was rapidly controlled by implementing
strict infection control interventions. The implementation
of an integrated antimicrobial stewardship program led to
an overall reduction of vancomycin and broad-spectrum
antibiotic use [9]. During the 7 years of this study, aggre-
gate and individual-patient vancomycin-exposure were
not found to be associated with VRE-BSI among hospital-
ized children. Similarly, Duchon and colleagues reported
that neonates colonized and/or infected with VRE had less
days of vancomycin therapy when compared with infants
hospitalized in the same intensive care unit who were not
colonized with VRE [2].
Conclusions
Controlling the forces driving the emergence of invasive
VRE infection requires an interdisciplinary approach and
commitment. Furthermore, studies assessing the impact
of antimicrobial stewardship interventions and emergence
of antibiotic resistance could be bias by unrecognized
nosocomial transmission of multidrug-resistant organ-
isms. Molecular epidemiology is a powerful tool to discern
between antibiotic exposure and hospital transmission as
potential sources of VRE-BSI. In our experience, closevigilance of environmental contamination and enforce-
ment of infection prevention and antibiotic policies
proved efficient to control nosocomial transmission and
reduce the rates of VRE-BSI in subsequent years. These
strategies are warranted to reduce mortality and costs as-
sociated with VRE-BSI among the most vulnerable hospi-
talized pediatric patients.
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